Leukemia, Myelomonocytic, Juvenile
"Leukemia, Myelomonocytic, Juvenile" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A leukemia affecting young children characterized by SPLENOMEGALY, enlarged lymph nodes, rashes, and hemorrhages. Traditionally classed as a myeloproliferative disease, it is now considered a mixed myeloproliferative-mylelodysplastic disorder.
| Descriptor ID |
D054429
|
| MeSH Number(s) |
C04.557.337.539.525 C15.378.190.615.520
|
| Concept/Terms |
Leukemia, Myelomonocytic, Juvenile- Leukemia, Myelomonocytic, Juvenile
- Leukemia, Juvenile Myelomonocytic
- Juvenile Chronic Myelogenous Leukemia
- Juvenile Myelomonocytic Leukemia
- Juvenile Myelomonocytic Leukemias
- Myelomonocytic Leukemia, Juvenile
- Myelomonocytic Leukemias, Juvenile
|
Below are MeSH descriptors whose meaning is more general than "Leukemia, Myelomonocytic, Juvenile".
Below are MeSH descriptors whose meaning is more specific than "Leukemia, Myelomonocytic, Juvenile".
This graph shows the total number of publications written about "Leukemia, Myelomonocytic, Juvenile" by people in this website by year, and whether "Leukemia, Myelomonocytic, Juvenile" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 3 | 0 | 3 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leukemia, Myelomonocytic, Juvenile" by people in Profiles.
-
Juvenile myelomonocytic leukemia; moving forward. Leukemia. 2023 03; 37(3):720-722.
-
Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis. Blood. 2022 09 22; 140(12):1408-1418.
-
Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Exp Hematol. 2022 11; 115:44-53.
-
Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia. Leukemia. 2022 08; 36(8):2097-2107.
-
Therapy-related myeloid neoplasms resembling juvenile myelomonocytic leukemia: a case series and review of the literature. Pediatr Blood Cancer. 2022 05; 69(5):e29499.
-
LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents. Leuk Lymphoma. 2020 06; 61(6):1493-1499.
-
Sustained remission with azacitidine monotherapy and an aberrant precursor B-lymphoblast population in juvenile myelomonocytic leukemia. Pediatr Blood Cancer. 2019 10; 66(10):e27905.
-
Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells. Leukemia. 2019 01; 33(1):181-190.
-
CMML/JMML PDXs: as easy as 1, 2, NSG-SGM3. Blood. 2017 07 27; 130(4):385-386.
-
The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet. 2015 Nov; 47(11):1326-1333.